---
title: 'CAR T-Cell therapy for Myeloma: Where are we now and what is needed to move
  CAR T-cells forward to earlier lines of therapy? Expert Panel Opinion from the American
  Society for Transplantation and Cellular Therapy'
date: '2023-11-01'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37913909/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20231102180650&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Since 2021, two B-Cell Maturation Antigen (BCMA) directed chimeric antigen
  receptor T-cell (CAR T-cell) therapies, Idecabtagene vicleucel (ide-cel), and ciltacabtagene
  autoleucel (cilta-cel), have been approved by the US FDA for relapsed or refractory
  multiple myeloma (RRMM) after four or more prior lines of therapy including an immunomodulatory
  drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody. The two products
  have both shown unprecedented activity in RRMM, but relapses ...
disable_comments: true
---
Since 2021, two B-Cell Maturation Antigen (BCMA) directed chimeric antigen receptor T-cell (CAR T-cell) therapies, Idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta-cel), have been approved by the US FDA for relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody. The two products have both shown unprecedented activity in RRMM, but relapses ...